

(21) Application No: 2218419.6
 (22) Date of Filing: 10.05.2021
 Date Lodged: 07.12.2022
 (30) Priority Data:
 (31) 63022309 (32) 08.05.2020 (33) US
 (86) International Application Data:
 PCT/US2021/031541 En 10.05.2021
 (87) International Publication Data:
 WO2021/226576 En 11.11.2021

(51) INT CL:
 C07K 16/28 (2006.01)
 (56) Documents Cited:
 WO 2019/073080 A1 WO 2018/190719 A2
 WO 2018/149938 A1
 NAN GUO RING ET AL, "Anti-SIRP[alpha] antibody immunotherapy enhances neutrophil and macrophage antitumor activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, US, (20171120), doi:10.1073/pnas.1710877114, ISSN 0027-8424, [X] 1,14,16-31,42-45,54-56,71,81,84-89 * figures 5c,5d *
 (58) Field of Search:
 INT CL C07K
 Other: EPO-Internal, BIOSIS, EMBASE, Sequence search

(71) Applicant(s):
 Electra Therapeutics, Inc.
 681 (3rd Floor), Gateway Boulevard,
 South San Francisco 94080, California,
 United States of America
 (72) Inventor(s):
 Sandip Panicker
 Adam David Rosenthal
 Eileen Lingshu Rose
 (74) Agent and/or Address for Service:
 Cooley (UK) LLP
 22 Bishopsgate, London, EC2N 4BQ, United Kingdom

(54) Title of the Invention: **SIRP alpha and SIRP beta 1 antibodies and uses thereof**
 Abstract Title: **SIRP ALPHA AND SIRP BETA 1 ANTIBODIES AND USES THEREOF**

(57) Provided herein are antibodies that bind signal regulatory protein SIRP α , SIRP β 1, or a combination of SIRP α and SIRP β 1, and methods of using such antibodies. In some embodiments, the antibodies are human monoclonal antibodies that bind human SIRP α and/or SIRP β 1. In some embodiments, the antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of myeloid cells, or a disease or condition associated with SIRP α and/or SIRP β 1 activity.

FIG. 1B

